Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Kanzler

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Oncology Research and Treatment|September 9, 2024
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS TrialMagdalena K Scheck, Thorsten O Goetze, Thomas J Ettrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)Dominik P Modest, Uwe M Martens, Jorge Riera-Knorrenschild, et al.
Oncology Research and Treatment|April 2, 2024
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114)Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, et al.
British Journal of Cancer|November 23, 2023
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trialHans-Joachim Schmoll, Julia Mann, Fabian Meinert, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh<sup>®TM</sup>) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic CancerKlara Dorman, Stefan Boeck, Robert J Snijder, et al.
BMC Cancer|September 2, 2016
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker programMarkus Moehler, Irina Gepfner-Tuma, Annett Maderer, et al.
BMC Cancer|April 13, 2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialCarl Christoph Schimanski, Markus Möhler, Michael Schön, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Oncology Research and Treatment|September 9, 2024
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS TrialMagdalena K Scheck, Thorsten O Goetze, Thomas J Ettrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)Dominik P Modest, Uwe M Martens, Jorge Riera-Knorrenschild, et al.
Oncology Research and Treatment|April 2, 2024
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114)Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, et al.
British Journal of Cancer|November 23, 2023
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trialHans-Joachim Schmoll, Julia Mann, Fabian Meinert, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh<sup>®TM</sup>) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic CancerKlara Dorman, Stefan Boeck, Robert J Snijder, et al.
BMC Cancer|September 2, 2016
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker programMarkus Moehler, Irina Gepfner-Tuma, Annett Maderer, et al.
BMC Cancer|April 13, 2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialCarl Christoph Schimanski, Markus Möhler, Michael Schön, et al.
Pageof 5